Invite AW.indd
Transcription
Invite AW.indd
Mini-Symposium You will have the opportunity to attend up to four `mini-symposia’ sessions. A selection of the mini-symposia available is provided below. A full list of available sessions and information on how to pre-register will be provided. Len Calabrese Managing Comorbidities in Rheumatologic Diseases Tom Huizinga Predicting Clinical Response – Biomarkers and Genetics Georgy Nagy Clinical Cases – Management of the Difficult RA patient Claire Bombardier Quality Indicators in RA Roy Fleischmann Oral Therapies – Clinical Data Walter Grassi Fred Joshua To Be or Not to Be in Remission: Can Ultrasound Guide Us? Annelies Boonen Laure Gossec Patient Reported Outcomes: Can Patients Tell Us More? Maxime Dougados Filip Van den Bosch Update in Spondyloarthropathies Robert Landewé Xenofon Baraliakos AxSpA: Interpretation of Imaging (X-ray, MRI) Astrid van Tubergen Epidemiology of Axial SpA Fred Houssiau Updates in the Management of Renal Disease in SLE Speaker TBC Cardiovascular Risk Management in SLE Speaker TBC Family Planning in SLE Thomas Dörner Treatment Goals and Disease Activity Assessment in SLE Georg Schett Osteoimmunology Rik Lories Piet Geusens Bone Biology and Novel Osteoporosis Agents Stephen Hall Nicolò Pipitone Managing Vasculitis Dominique Baeten Updates in Basic Immunology Athol Wells Interstitial Lung Disease THE FOURTH INTERNATIONAL IMMUNOLOGY SUMMIT Clinical Implications of Scientific Breakthroughs in Immune-Mediated Diseases 21st to 23rd February 2013, Prague, Czech Republic Chaired by Peter Nash CME accreditation applied for This meeting is sponsored by UCB. CME accreditation applied for. Date of Preparation: October 2012 Code: IMNL-SCT-016659-102012 © UCB S.A. 2012. All rights reserved. Dear Colleagues and Friends, On behalf of myself and our faculty of distinguished specialists I am delighted to invite you to join us at the Fourth International Immunology Summit. Within the field of immunology, analogous to the challenge of climbing a mountain, we have faced a steep climb in the treatment of our patients. Our initial goals of symptom control and disease modification have been surpassed in many cases, and we continue to advance up the treatment pyramid as our focus increasingly shifts to remission and drug-free remission. This meeting will consider the scientific data and clinical guidance that can help us to continue this advance, and will close with discussions of our hopes for the future, of reaching the peak of management through the cure, and ultimately prevention of immunological conditions. This meeting will review the latest scientific developments across immune-mediated diseases and consider how these novel updates can be implemented in the clinic to improve the care of our patients. The programme will cover a wide range of relevant topics including: • New pathways and targets in immunology • Managing comorbidities in rheumatologic diseases • Scientific approaches to early aggressive treatment in RA and translation of clinical trial data into daily practice • Pathogenesis of axial SpA and PsA and novel management approaches • Future developments in rheumatic disease imaging • Novel pathways and therapies in SLE • Novel pathways and therapies in osteoporosis The Summit will provide the opportunity for discussion, interaction, networking and debate with many leading experts in their respective fields. The meeting will start at 11am on the morning of Thursday 21st February and finish at lunchtime on Saturday 23rd February. In addition to the main plenary sessions you will have the opportunity to attend up to four highly interactive ‘mini-symposia’ sessions, providing the opportunity to consider the most novel developments across a wide range of topics most relevant to the management of our patients. I very much look forward to welcoming you to what promises to be a highly exciting, interactive and enjoyable meeting. Kind regards Programme Thursday 21st February 2013 0940 – 1010 Coffee 1000 – 1100 Arrivals and Coffee 1010 – 1040 Axial SpA – Pathogenesis and Burden of Disease 1100 – 1110 Welcome and Introduction from the Course Director Désirée van der Heijde (NL) 1040 – 1110 Update on Trials and Novel Therapies in SpA Filip van den Bosch (Belgium) 1110 – 1120 Questions and Answer Session 1120 – 1250 Mini-Symposium Session 2 1250 – 1420 Lunch Future Developments in Rheumatic Disease Imaging Robert Landewé (NL) 1500 – 1530 Basic Science – Pathogenesis of SLE Thomas Dörner (Germany) 1530 – 1600 Novel Therapies in SLE Joan Merrill (USA) 1600 – 1615 Questions and Answer Session 1615 – 1645 Coffee Peter Nash (Australia) Updates in Immunology 1110 – 1140 New Pathways and Targets in Immunology Dominique Baeten (NL) 1140 – 1210 Introduction of Novel Agents – Implications for Clinical Practice Peter Taylor 1210 – 1220 Questions and Answer Session 1420 – 1500 1220 – 1330 Lunch SLE Management of Rheumatological Diseases 1330 – 1400 Managing Comorbidities in Rheumatologic Diseases Len Calabrese (US) 1400 – 1430 Family Planning and Pregnancy in Immunological Disease Speaker to be confirmed 1430 – 1500 Advances in Interstitial Lung Disease – Classification, Investigation & Management Athol Wells (UK) 1645 – 1815 Mini-Symposium Session 3 1500 – 1515 Questions and Answer Session 2000 Summit Dinner 1515 – 1545 Coffee Saturday 23rd February 2013 Rheumatoid Arthritis 1545 – 1615 Biologic Agents – An Update of Safety Data Xavier Mariette (France) 1615 – 1645 Early and Aggressive Management of RA Speaker to be confirmed Josef Smolen (Austria) 0830 – 1000 Mini-Symposium Session 4 1000 – 1030 Coffee Bone Biology 1030 – 1100 Updates in Osteoporosis Eugene McCloskey (UK) 1100 – 1130 Novel Pathways in Osteoporosis Christian Roux (France) 1645 – 1715 Translating Trial Data into Clinical Practice 1715 – 1730 Questions and Answer Session 1730 – 1900 Mini-Symposium Session 1 1130 – 1140 Questions and Answer Session 2000 Buffet Dinner 1140 – 1210 Reaching the Summit – The Future of Immunological Disease Management 1210 – 1230 Meeting Summary and Close 1230 – 1330 Lunch Friday 22nd February 2013 axSpA and PsA 0830 – 0900 Pathogenesis and Novel Targets in PsA Chris Ritchlin (US) Peter Nash MBBS (hons) FRACP (Course Director) 0900 – 0930 Update on Trials and Novel Therapies in PsA Doug Veale (Ireland) Associate Professor, Department of Medicine, University of Queensland Director of the Rheumatology Research Unit, Sunshine Coast, Australia 0930 – 0940 Questions and Answer Session Programme may be subject to minor changes Speaker to be confirmed